Aberrant methylation of HTATIP2 and UCHL1 as a predictive biomarker for cholangiocarcinoma

Nanok,Chaiyachet; Jearanaikoon,Patcharee; Proungvitaya,Siriporn; Limpaiboon,Temduang

doi:10.3892/mmr.2017.8319

Aberrant methylation of HTATIP2 and UCHL1 as a predictive biomarker for cholangiocarcinoma

Authors:
- Chaiyachet Nanok
- Patcharee Jearanaikoon
- Siriporn Proungvitaya
- Temduang Limpaiboon
View Affiliations

Affiliations: Department of Clinical Chemistry, Centre for Research and Development of Medical Diagnostic Laboratories, Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen 40002, Thailand
Published online on: December 19, 2017 https://doi.org/10.3892/mmr.2017.8319
Pages: 4145-4153

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cholangiocarcinoma (CCA) is the most common primary liver cancer in Northeastern Thailand where liver fluke infection is highly endemic. Although aberrant DNA methylation in CCA has been reported by several investigators, little is known regarding the associations between them. In the present study, the results obtained from our previously published methylation array were analyzed and 10 candidate genes involved in DNA repair [protein phosphatase 4 catalytic subunit (PPP4C)], apoptosis [runt related transcription factor 3 (RUNX3), interferon regulatory factor 4 (IRF4), ubiquitin C‑terminal hydrolase L1 (UCHL1) and tumor protein p53 inducible protein 3 (TP53I3)], cell proliferation [cyclin D2 (CCND2) and Ras association domain family member 1 (RASSF1)], drug metabolism [aldehyde dehydrogenase 1 family member A3 (ALDH1A3) and solute carrier family 29 member 1 (SLC29A1)] and angiogenesis [human immunodeficiency virus‑1 tat interactive protein 2 (HTATIP2)] were selected for quantification of their methylation levels in 54 CCA and 19 adjacent normal tissues using methylation‑sensitive high‑resolution melting. The associations between the methylation status of the individual genes and clinical parameters were statistically analyzed. High methylation levels were observed in UCHL1, IRF4, CCND2, HTATIP2 and TP53I3. The median methylation level of UCHL1 was 57.3% (range, 3.15 to 88.7%) and HTATIP2 was 13.6% (range, 7.5 to 36.7%). By contrast, low methylation of HTATIP2 and UCHL1 was identified in adjacent normal tissues. The methylation status of HTATIP2 and UCHL1 was associated with patients' overall survival. CCA patients with high methylation of HTATIP2 and low methylation of UCHL1 exhibited longer overall survival. In addition, multivariate Cox regression analysis demonstrated that UCHL1 methylation was an independent factor for CCA with hazard ratio of 1.81 (95% confidence interval, 1.01‑3.25) in high methylation group. The combination of HTATIP2 and UCHL1 methylation status strongly supported their potential predictive biomarker in which patients with CCA who had high methylation of HTATIP2 and low methylation of UCHL1 showed longer overall survival than those with low HTATIP2 methylation and high UCHL1 methylation. In conclusion, the present study revealed the value of aberrant DNA methylation of HTATIP2 and UCHL1, which may serve as a potential predictive biomarker for CCA.

View Figures

View References

1	Mosconi S, Beretta GD, Labianca R, Zampino MG, Gatta G and Heinemann V: Cholangiocarcinoma. Crit Rev Oncol Hemat. 69:259–270. 2009. View Article : Google Scholar
2	Shaib Y and El-Serag HB: The epidemiology of cholangiocarcinoma. Semin Liver Dis. 24:115–125. 2004. View Article : Google Scholar : PubMed/NCBI
3	Zhang H, Yang T, Wu M and Shen F: Intrahepatic cholangiocarcinoma: Epidemiology, risk factors, diagnosis and surgical management. Cancer Lett. 379:198–205. 2016. View Article : Google Scholar : PubMed/NCBI
4	Bridgewater J, Galle PR, Khan SA, Llovet JM, Park JW, Patel T, Pawlik TM and Gores GJ: Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol. 60:1268–1289. 2014. View Article : Google Scholar : PubMed/NCBI
5	Vatanasapt V, Uttaravichien T, Mairiang EO, Pairojkul C, Chartbanchachai W and Haswell-Elkins M: Cholangiocarcinoma in north-east Thailand. Lancet. 335:116–117. 1990. View Article : Google Scholar : PubMed/NCBI
6	Shin HR, Oh JK, Masuyer E, Curado MP, Bouvard V, Fang YY, Wiangnon S, Sripa B and Hong ST: Epidemiology of cholangiocarcinoma: An update focusing on risk factors. Cancer Sci. 101:579–585. 2010. View Article : Google Scholar : PubMed/NCBI
7	Sripa B, Bethony JM, Sithithaworn P, Kaewkes S, Mairiang E, Loukas A, Mulvenna J, Laha T, Hotez PJ and Brindley PJ: Opisthorchiasis and Opisthorchis-associated cholangiocarcinoma in Thailand and Laos. Acta Trop. 120 Suppl 1:S158–S168. 2011. View Article : Google Scholar : PubMed/NCBI
8	Luvira V, Nilprapha K, Bhudhisawasdi V, Pugkhem A, Chamadol N and Kamsa-ard S: Cholangiocarcinoma patient outcome in Northeastern Thailand: Single-center prospective study. Asian Pac J Cancer Prev. 17:401–406. 2016. View Article : Google Scholar : PubMed/NCBI
9	Malhi H and Gores GJ: Cholangiocarcinoma: Modern advances in understanding a deadly old disease. J Hepatol. 45:856–867. 2006. View Article : Google Scholar : PubMed/NCBI
10	Sriraksa R, Zeller C, Dai W, Siddiq A, Walley AJ, Limpaiboon T and Brown R: Aberrant DNA methylation at genes associated with a stem cell-like phenotype in cholangiocarcinoma tumors. Cancer Prev Res (Phila). 6:1348–1355. 2013. View Article : Google Scholar : PubMed/NCBI
11	McCarthy DJ and Smyth GK: Testing significance relative to a fold-change threshold is a TREAT. Bioinformatics. 25:765–771. 2009. View Article : Google Scholar : PubMed/NCBI
12	Zhang X, Ozawa Y, Lee H, Wen YD, Tan TH, Wadzinski BE and Seto E: Histone deacetylase 3 (HDAC3) activity is regulated by interaction with protein serine/threonine phosphatase 4. Genes Dev. 19:827–839. 2005. View Article : Google Scholar : PubMed/NCBI
13	Liu Z, Zhang X, Xu X, Chen L, Li W, Yu H, Sun Y, Zeng J and Jia J: RUNX3 inhibits survivin expression and induces cell apoptosis in gastric cancer. Eur J cell Biol. 93:118–126. 2014. View Article : Google Scholar : PubMed/NCBI
14	Ju XL, Ishikawa TO, Naka K, Ito K, Ito Y and Oshima M: Context-dependent activation of Wnt signaling by tumor suppressor RUNX3 in gastric cancer cells. Cancer Sci. 105:418–424. 2014. View Article : Google Scholar : PubMed/NCBI
15	Imaizumi Y, Kohno T, Yamada Y, Ikeda S, Tanaka Y, Tomonaga M and Matsuyama T: Possible involvement of interferon regulatory factor 4 (IRF4) in a clinical subtype of adult T-cell leukemia. Jpn J Cancer Res. 92:1284–1292. 2001. View Article : Google Scholar : PubMed/NCBI
16	Xiang T, Li L, Yin X, Yuan C, Tan C, Su X, Xiong L, Putti TC, Oberst M, Kelly K, et al: The ubiquitin peptidase UCHL1 induces G0/G1 cell cycle arrest and apoptosis through stabilizing p53 and is frequently silenced in breast cancer. PLoS One. 7:e297832012. View Article : Google Scholar : PubMed/NCBI
17	Moll UM and Slade N: p63 and p73: Roles in development and tumor formation. Mol Cancer Res. 2:371–386. 2004.PubMed/NCBI
18	Sicinski P, Donaher JL, Geng Y, Parker SB, Gardner H, Park MY, Robker RL, Richards JS, McGinnis LK, Biggers JD, et al: Cyclin D2 is an FSH-responsive gene involved in gonadal cell proliferation and oncogenesis. Nature. 384:470–474. 1996. View Article : Google Scholar : PubMed/NCBI
19	Shivakumar L, Minna J, Sakamaki T, Pestell R and White MA: The RASSF1A tumor suppressor blocks cell cycle progression and inhibits cyclin D1 accumulation. Mol Cell Biol. 22:4309–4318. 2002. View Article : Google Scholar : PubMed/NCBI
20	Koppaka V, Thompson DC, Chen Y, Ellermann M, Nicolaou KC, Juvonen RO, Petersen D, Deitrich RA, Hurley TD and Vasiliou V: Aldehyde dehydrogenase inhibitors: A comprehensive review of the pharmacology, mechanism of action, substrate specificity and clinical application. Pharmacol Rev. 64:520–539. 2012. View Article : Google Scholar : PubMed/NCBI
21	Garcia-Manteiga J, Molina-Arcas M, Casado FJ, Mazo A and Pastor-Anglada M: Nucleoside transporter profiles in human pancreatic cancer cells: Role of hCNT1 in 2′,2′-difluorodeoxycytidine-induced cytotoxicity. Clin Cancer Res. 9:5000–5008. 2003.PubMed/NCBI
22	Ito M, Jiang C, Krumm K, Zhang X, Pecha J, Zhao J, Guo Y, Roeder RG and Xiao H: TIP30 deficiency increases susceptibility to tumorigenesis. Cancer Res. 63:8763–8767. 2003.PubMed/NCBI
23	Donninger H, Clark J, Rinaldo F, Nelson N, Barnoud T, Schmidt ML, Hobbing KR, Vos MD, Sils B and Clark GJ: The RASSF1A tumor suppressor regulates XPA-mediated DNA repair. Mol Cell Biol. 35:277–287. 2015. View Article : Google Scholar : PubMed/NCBI
24	Sriraksa R, Chaopatchayakul P, Jearanaikoon P, Leelayuwat C and Limpaiboon T: Verification of complete bisulfite modification using Calponin-specific primer sets. Clin Biochem. 43:528–530. 2010. View Article : Google Scholar : PubMed/NCBI
25	Wojdacz TK, Dobrovic A and Hansen LL: Methylation-sensitive high-resolution melting. Nat Protoc. 3:1903–1908. 2008. View Article : Google Scholar : PubMed/NCBI
26	NicAmhlaoibh R and Shtivelman E: Metastasis suppressor CC3 inhibits angiogenic properties of tumor cells in vitro. Oncogene. 20:270–275. 2001. View Article : Google Scholar : PubMed/NCBI
27	King FW and Shtivelman E: Inhibition of nuclear import by the proapoptotic protein CC3. Mol Cell Biol. 24:7091–7101. 2004. View Article : Google Scholar : PubMed/NCBI
28	Shtivelman E: A link between metastasis and resistance to apoptosis of variant small cell lung carcinoma. Oncogene. 14:2167–2173. 1997. View Article : Google Scholar : PubMed/NCBI
29	Whitman S, Wang X, Shalaby R and Shtivelman E: Alternatively spliced products CC3 and TC3 have opposing effects on apoptosis. Mol Cell Biol. 20:583–593. 2000. View Article : Google Scholar : PubMed/NCBI
30	Lu B, Ma Y, Wu G, Tong X, Guo H, Liang A, Cong W, Liu C, Wang H, Wu M, et al: Methylation of Tip30 promoter is associated with poor prognosis in human hepatocellular carcinoma. Clin Cancer Res. 14:7405–7412. 2008. View Article : Google Scholar : PubMed/NCBI
31	Chen X, Cao X, Dong W, Luo S, Suo ZH and Jin Y: Expression of TIP30 tumor suppressor gene is down-regulated in human colorectal carcinoma. Dig Dis Sci. 55:2219–2226. 2010. View Article : Google Scholar : PubMed/NCBI
32	Hartnett L and Egan LJ: Inflammation, DNA methylation and colitis-associated cancer. Carcinogenesis. 33:723–731. 2012. View Article : Google Scholar : PubMed/NCBI
33	Yu J, Tao Q, Cheung KF, Jin H, Poon FF, Wang X, Li H, Cheng YY, Rocken C, Ebert MP, et al: Epigenetic identification of ubiquitin carboxyl-terminal hydrolase L1 as a functional tumor suppressor and biomarker for hepatocellular carcinoma and other digestive tumors. Hepatology. 48:508–518. 2008. View Article : Google Scholar : PubMed/NCBI
34	Waraya M, Yamashita K, Ema A, Katada N, Kikuchi S and Watanabe M: Exclusive association of p53 mutation with super-high methylation of tumor suppressor genes in the p53 pathway in a unique gastric cancer phenotype. PLoS One. 10:e01399022015. View Article : Google Scholar : PubMed/NCBI
35	Xu T, Jin Z, Yuan Y, Zheng H, Li C, Hou W, Guo Q and Hua B: Tat-Interacting protein 30 (TIP30) expression serves as a new biomarker for tumor prognosis: A systematic review and meta-analysis. PLoS One. 11:e01684082016. View Article : Google Scholar : PubMed/NCBI
36	Zhu M, Yin F, Fan X, Jing W, Chen R, Liu L, Zhang L, Liu Y, Liang Y, Bu F, et al: Decreased TIP30 promotes Snail-mediated epithelial-mesenchymal transition and tumor-initiating properties in hepatocellular carcinoma. Oncogene. 34:1420–1431. 2015. View Article : Google Scholar : PubMed/NCBI
37	Zhu M, Yin F, Yang L, Chen S, Chen R, Zhou X, Jing W, Fan X, Jia R, Wang H, et al: Contribution of TIP30 to chemoresistance in laryngeal carcinoma. Cell Death Dis. 5:e14682014. View Article : Google Scholar : PubMed/NCBI
38	Zhao J, Zhang X, Shi M, Xu H, Jin J, Ni HD, Yang SL, Dai JX, Wu MC and Guo YJ: TIP30 inhibits growth of HCC cell lines and inhibits HCC xenografts in mice in combination with 5-FU. Hepatology. 44:205–215. 2006. View Article : Google Scholar : PubMed/NCBI
39	Jiang C, Pecha J, Hoshino I, Ankrapp D and Xiao H: TIP30 mutant derived from hepatocellular carcinoma specimens promotes growth of HepG2 cells through up-regulation of n-cadherin. Cancer Res. 67:3574–3582. 2007. View Article : Google Scholar : PubMed/NCBI
40	Dong X, Deng Q, Nie X, Zhang M, Jia W, Chen C, Xu C and Xu R: Downregulation of HTATIP2 expression is associated with promoter methylation and poor prognosis in glioma. Exp Mol Pathol. 98:192–199. 2015. View Article : Google Scholar : PubMed/NCBI
41	Bonazzi VF, Nancarrow DJ, Stark MS, Moser RJ, Boyle GM, Aoude LG, Schmidt C and Hayward NK: Cross-platform array screening identifies COL1A2, THBS1, TNFRSF10D and UCHL1 as genes frequently silenced by methylation in melanoma. PLoS One. 6:e261212011. View Article : Google Scholar : PubMed/NCBI
42	Xiang T, Li L, Yin X, Yuan C, Tan C, Su X, Xiong L, Putti T, Oberst M, Kelly K, et al: The ubiquitin peptidase UCHL1 induces G0/G1 cell cycle arrest and apoptosis through stabilizing p53 and is frequently silenced in breast cancer. PLoS One. 7:e297832012. View Article : Google Scholar : PubMed/NCBI
43	Li L, Tao Q, Jin H, van Hasselt A, Poon FF, Wang X, Zeng MS, Jia WH, Zeng YX, Chan AT and Cao Y: The tumor suppressor UCHL1 forms a complex with p53/MDM2/ARF to promote p53 signaling and is frequently silenced in nasopharyngeal carcinoma. Clin Cancer Res. 16:2949–2958. 2010. View Article : Google Scholar : PubMed/NCBI
44	Schroder C, Milde-Langosch K, Gebauer F, Schmid K, Mueller V, Wirtz RM, Meyer-Schwesinger C, Schluter H, Sauter G and Schumacher U: Prognostic relevance of ubiquitin C-terminal hydrolase L1 (UCH-L1) mRNA and protein expression in breast cancer patients. J Cancer Res Clin Oncol. 139:1745–1755. 2013. View Article : Google Scholar : PubMed/NCBI
45	Majchrzak-Celinska A, Paluszczak J, Szalata M, Barciszewska AM, Nowak S and Baer-Dubowska W: DNA methylation analysis of benign and atypical meningiomas: Correlation between RUNX3 methylation and WHO grade. J Cancer Res Clin Oncol. 141:1593–1601. 2015. View Article : Google Scholar : PubMed/NCBI
46	Majchrzak-Celinska A, Paluszczak J, Szalata M, Barciszewska AM, Nowak S, Kleszcz R, Sherba A and Baer-Dubowska W: The methylation of a panel of genes differentiates low-grade from high-grade gliomas. Tumor Biol. 36:3831–3841. 2015. View Article : Google Scholar
47	Ni W, Luo L, Ping Z, Yuan HP, Zhao XD and Xu W: Prognostic value of ALDH1A3 promoter methylation in glioblastoma: A single center experience in Western China. Asian Pac J Cancer Prev. 16:591–594. 2015. View Article : Google Scholar : PubMed/NCBI